| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 44.04 | 16.1% | 13.6% |
| Total Income | 44.04 | 16.1% | 13.6% |
| Expenditure | 59.26 | 4.9% | 8.9% |
| PBT | -33.09 | 11.1% | 3.3% |
| Net Profit | -33.13 | 11.1% | 3.3% |
| OPM | -34.56% | 29.74pp | 33.21pp |
| NPM | -75.21% | 23.00pp | 7.48pp |
| EPS | -3.82 | 11.6% | 1369.2% |
Karyopharm Reports Q3 2025 Financial Results; Revenue $44.0 Million
04 May 2026 · 4 May, 8:20 am
Summary
Karyopharm Therapeutics Inc. reported financial results for the third quarter ended September 30, 2025. Total revenue for the quarter was $44.0 million, compared to $38.8 million for the third quarter of 2024. U.S. XPOVIO net product revenue increased by 8.5% to $32.0 million. The company reaffirms its full-year 2025 total revenue guidance of $140 million to $155 million and U.S. XPOVIO net product revenue guidance of $110 million to $120 million. The company expects its existing liquidity will be sufficient to fund its planned operations into the second quarter of 2026.
Key Highlights
- 1
Total revenue for the third quarter of 2025 was $44.0 million, compared to $38.8 million for the third quarter of 2024.
- 2
U.S. XPOVIO net product revenue was $32.0 million in the third quarter of 2025, an increase of 8.5% compared to the third quarter of 2024.
- 3
Royalty revenue increased to $1.5 million in the third quarter of 2025 compared to $0.9 million in the third quarter of 2024.
- 4
The company reaffirms full-year 2025 total revenue guidance of $140 million to $155 million.
- 5
The company reaffirms U.S. XPOVIO net product revenue guidance of $110 million to $120 million.
- 6
Loss from operations for the third quarter of 2025 was $15.2 million, an improvement of approximately 42% compared to a loss of $26.3 million in the third quarter of 2024.
- 7
Cash, cash equivalents, restricted cash and investments as of September 30, 2025 totaled $46.2 million.
Management Comments
Richard Paulson
“This has been a very productive quarter as we have strengthened our financial foundation and made meaningful clinical progress with enrollment completion of our Phase 3 SENTRY trial in myelofibrosis, marking a pivotal milestone for Karyopharm,” “With SENTRY enrollment complete, our teams remain focused on clinical trial execution, preparing for top-line data in March, potential regulatory filings, and commercial launch readiness, as we work to redefine the standard-of-care for frontline myelofibrosis patients, pending regulatory approvals.”
Informational and educational content only. Not investment advice.